The combination of systemic enzymes and probiotics will be a silver lining for people suffering from ‘Long COVID’ symptoms and fatigue. 

FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 2021

REVENUES:

• Revenues on a consolidated basis rose to ₹1,370 million in Q1FY22 from ₹1,105 million during Q1FY21, with a growth of 24%. 
• Profit: Consolidated EBITDA during Q1FY22 stands at ₹628 million compared to ₹517 million during Q1FY21, with a growth of 21%. 
• PBT: Profit Before Tax stands at ₹550 million during Q1FY22 as against ₹498 million in the previous year, with a Year-on-Year growth of 10%. 
• PAT: Profit After Tax stands at ₹399 million during Q1FY22 compared to ₹348 million during Q1FY21, with a growth of 15%. 
• Margins: EBITDA margin during Q1FY22 stands at 46% as compared to 47% in Q1FY21.  
• The PBT margin stands at 40% during Q1FY22 as against 45% in Q1FY21. Similarly, PAT margin stands at 29% during Q1 FY22 as against 31% in Q1 FY21.

SALES: 

• International Sales: The total revenue stands at ₹791 million during Q1FY22 compared to ₹585 million in Q1FY21, a growth of 35%. The revenue grew by 10% in the Americas, 79% in Europe, 158% in Asia (ex-India), and 633% in the rest of the world. 
• Domestic sales: It accounted for ₹ 579 million in Q1 FY22 compared to ₹ 520 million in Q1 FY21, an increase of 11%. The domestic sales constituted about 42% of revenue from operations during Q1 FY22 compared to 47% during Q1 FY21. International sales were 58% of revenue from operations as compared to 53% during Q1 FY21.

FINANCIAL SNAPSHOT: (FY21 VS FY20)

• FY2021 sales up 13 percent Year-on-Year to Rs.5,018 million against ₹4,440 million in FY2020
• EBITDA for FY2021 stands at ₹2,315 million against ₹2,023 million in FY2020, up 14 percent
• EBITDA margin for FY2021 stands at 46 percent as against 46 percent in FY2020
• Net Profit during FY2021 jumped by 14 percent at ₹1,515 million against ₹1,330 million in FY2020.
• During FY2021, on a consolidated basis, R&D expenses stood at ₹178 million, which was 3.55 percent of the net sales compared to ₹144 million in FY2020, which was 3.25 percent of the net sales.

MUMBAI, AUGUST 21, 2021 (GPN): The COVID-19 pandemic has seen Mumbai-based specialty biotech company — Advanced Enzymes Technologies Ltd (NSE: ADVENZYMES; BSE: 540025) riding the new normal.

To ramp up sales of its researched-backed chemical-free post-COVID adaptive immune support bundle — ImmunoSEB and Biome Ultra (ProbioSEB CSC3), the company has beefed up its omnichannel presence across India and globally.

After tasting its runaway success in the US markets amidst the pandemic, AET decided to list its flagship immune support brands — ImmunoSEB and Biome Ultra, across online marketplaces in India to target a larger swath of pill-fatigued, healthy agers, immunity conscious millennials, and Gen Z.

The products are currently available globally on the leading e-commerce marketplace — Amazon. In a move to further shore up its direct-to-customer (D2C) omnichannel retailing business, AET is all set to unveil its online store — ‘Advanced Enzymes e-Direct Store’ in September 2021 to help customers choose from a wide range of health support products.

Tailored it to the local context, it’s currently working on various smart pivots and strategies to garner the share of silver linings in a bleak pandemic situation.

The company has invested in a big way to create captivated and customer-friendly user interfaces that offer the real omnichannel experience for young tech-savvy health conscious customers. 

ImmunoSEB and Biome Ultra (ProbioSEB CSC3) comprise systemic enzymes and probiotics, which help in strengthening immunity and are most effective in reducing ‘long COVID’ afflictions.

ImmunoSEB is a systemic proteolytic enzyme supplement containing extracts from papayas and pineapples. Papaya contains papain enzyme, while bromelain is found in fresh pineapples.

It helps in rejuvenating cells, tissues, and organs alleviate inflammation and fatigue. Similarly, Biome Ultra is a probiotics formulation which is a formulation of healthy bacillus species strains. It helps in destroying toxins, improves imbalance of gut microflora, and enhances digestion & absorption of nutrients.

Soon after the online launch, the company witnessed a double-digit surge in demand for its probiotic products in the US markets, thanks to the rising awareness of gastrointestinal and immune healthcare, said Mr. Mukund Madhusudan Kabra, Whole-Time Director, Advanced Enzyme Technologies Limited.

Though the probiotics market is witnessing gradual growth globally, India remains mostly underpenetrated. According to Mr. Kabra, there is a strong demand for chemical free and clinically proven immune-boosting supplements from society’s middle and upper strata.

The lack of remedy for chronic diseases and side-effects of standard medicines are forcing people to rush towards healthier, natural, and chemical-free adaptive immune therapies like ImmunoSEB and Biome Ultra.  

Research indicates immense growth in India’s probiotics market in the next three to four years. It’s expected to grow at a CAGR of 13.56 percent to notch up a market size of $961.856 million by the end of 2025. It currently stands at $448.456 million, said Dr. Abhijit K. Rathi, Principal Scientist, AET.

According to the famous Greek physician Hippocrates of Kos, also known as the ‘father of medicine’ and accredited with conceiving the ‘Hippocratic Oath,’ once alluded saying: ‘All diseases originate in the gut.’ 

“One of the pivotal players in the immune health system is the gut, which is perpetually open to toxins and alien antigens stemming from microbes and food. The gut is the key immune organ in the body. Strangely, it largely remains an elapsed organ in the overall health system till date. There are over 3,000 bacterial species that inhabit the gut, which has a synergetic relationship with the human body and also known as gut-brain axis (GBA). Likewise, there are trillions of bacteria in our gut that shapes ecology similar to a ‘flower garden,” elucidated Dr. Rathi.

“The cost of COVID-19 treatment indicated how financially disastrous and crippling an illness could be. Cost of hospitalization has become something everyone wants to avoid, and people have realized it is best to adopt preventive measures,” he said.

“While the world is beleaguered with the devastating virus each day, no medicine vows absolute protection, and vaccination seems to be the only possible option at the moment. We at AET are extensively conducting innovative research on chemical free methods to enhance the immunity, which can help your body fight the rapidly mutating virus with each passing day,” said Dr. Rathi.

Meanwhile, AET plans to introduce more enzymes and probiotics products in its kitty in various genres, including human nutrition for immunity development, functional health food, gut health, and various nutraceutical applications. The company is determined to launch additional products on immunity development and digestion improvement to elevate nutritional levels in feeds in the animal nutrition segment. ENDS

ABOUT ADVANCED ENZYME TECHNOLOGIES LIMITED

Incorporated in 1989, Advanced Enzyme Technologies Limited (AET) is a research-driven global company with leadership in manufacturing enzymes and probiotics. The company offers eco-safe solutions to various industries, such as human health care & nutrition, animal nutrition, baking, fruit & vegetable processing, brewing & malting, grain processing, protein modification, dairy processing, specialty applications, textile processing, and to name a few.

The company aims to supplant traditionally used chemicals with eco-friendly enzymatic solutions. It provides customized and effective enzyme solutions coupled with the best in technical advice and superior services. It has seven state-of-the-art manufacturing units and six R&D located across India, Germany, and the US. It exports to over 45 countries spread across six continents.

On January 11, 2021, AET acquired a majority stake in SciTech Specialties specializing in effervescent-based products for Rs.316 million. The acquisition synergized the company with two manufacturing facilities and one R&D facility. It led to a growth of 1.8 percent. Currently, the company has nine manufacturing units and seven R&D facilities.